Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine/X
Jun 23, 2025, 13:27

Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE

Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:

“RivaGate in DC at ⁦ISTH⁩ 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”

Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE

More posts from ISTH 2025 on Hemostasis Today.

Apixaban COPRRA Gunnar Henrik Heine Hematology Hemostasis Today ISTH 2025 VTE
NewsFeed